New immune biomarkers uncovered with foralumab treatment
Intranasal foralumab can modulate a number of immune cell types in people with nonactive secondary progressive multiple sclerosis (SPMS),…
Articles by Katherine Poinsatte, PhD
Clinical trial testing sublingual cladribine planned for next year
Bionxt Solutions is preparing to launch a pilot clinical trial to compare BNT23001, its new sublingual, or under-the-tongue, formulation of…
NYU scientist recognized for work on MS cognitive impairments
Cognitive rehabilitation scientist Yael Goverover, PhD, has been recognized with the title of Fellow of the American Congress of Rehabilitation…
FDA OKs Phase 1 clinical trial of IMPT-514 for hard-to-treat MS
The U.S. Food and Drug Administration (FDA) has given the green light to Immpact Bio to conduct a Phase…
New investment to advance Abata’s T-cell therapy for progressive MS
Abata Therapeutics has received an investment from Bristol Myers Squibb to support the development of its experimental regulatory T-cell…
First healthy participant dosed in Phase 1 trial of IMP761 for MS
A Phase 1 clinical trial that’s testing IMP761, an experimental treatment for multiple sclerosis (MS) and other autoimmune conditions,…
Potential MS therapy IMP761 to be tested in healthy volunteers
Immutep has been cleared to start a Phase 1 clinical trial in the Netherlands to test IMP761, its experimental…
Subcutaneous Ocrevus gets UK approval for relapsing MS, PPMS
A subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) received approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA)…
Phase 1 trial of ABA-101 for progressive MS gets FDA OK
Abata Therapeutics is expected to launch a Phase 1 clinical trial by the end of the year to test…